Vincenzo Di Noia

Vincenzo Di Noia

Auto-generated profile, based on publicly available information

Vincenzo Di Noia

Medical Oncology 1 Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2020 in Cancers
Verified
Journal Article
Open access
PDF file
MFMiriam Grazia Ferrara
Miriam Grazia Ferrara
VNVincenzo Di Noia
Vincenzo Di Noia
DED’Argento Ettore
D’Argento Ettore
EVEmanuele Vita
Emanuele Vita
PDPaola Damiano
Paola Damiano
EBEmilio Bria
Emilio Bria
Before the introduction of tyrosine kinase inhibitors (TKIs) for a particular subgroup of patients, despite platinum-based combination chemotherapy, the majority of patients affected by non-small-cell lung cancer (NSCLC) did not live longer than one year. With deeper understanding of tumor molecular biology, treatment of NSCLC has progressively entered the era of treatment customization according to tumor molecular characteristics, as well as histology. All this information allowed the development of personalized molecular targeted therapies. A series of studies have shown that, in some cases, cancer cells can grow and survive as result of the presence of a single driver genomic abnormality. This phenomenon, called oncogene-addiction, more often occurs in adenocarcinoma histology, in non-smokers (except BRAF mutations, also frequent in smoking patients), young, and female patients. Several different driver mutations have been identified and many studies have clearly shown that upfront TKI monotherapy may improve the overall outcome of these patients. The greater efficacy of these drugs is also associated with a better tolerability and safety than chemotherapy, with fewer side effects and an extremely good compliance to treatment. The most frequent oncogene-addicted disease is represented by those tumors carrying a mutation of the epidermal growth factor receptor (EGFR). The development of first, second and third generation TKIs against EGFR mutations have dramatically changed the prognosis of these patients. Currently, osimertinib (which demonstrated to improve efficacy with a better tolerability in comparison with first-generation TKIs) is considered the best treatment option for patients affected by NSCLC harboring a common EGFR mutation. EML4-ALK-driven disease (which gene re-arrangement occurs in 3–7% of NSCLC), has demonstrated to be significantly targeted by specific TKIs, which have improved outcome in comparison with chemotherapy. To date, alectinib is considered the best treatment option for these patients, with other newer agents upcoming. Other additional driver abnormalities, such as ROS1, BRAF, MET, RET and NTRK, have been identified as a target mirroring peculiar vulnerability to specific agents. Oncogene-addicted disease typically has a low early resistance rate, but late acquired resistance always develops and therefore therapy needs to be changed when progression occurs. In this narrative review, the state of art of scientific literature about targeted therapy options in oncogene-addicted disease is summarized and critically discussed. We also aim to analyze future perspectives to maximize benefits for this subgroup of patients.

30 May 2020 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
ACAlessio Cortellini
Alessio Cortellini
MTMarcello Tiseo
Marcello Tiseo
Giuseppe BannaGiuseppe Banna
Giuseppe Banna
FCFederico Cappuzzo
Federico Cappuzzo
JAJoachim G. J. V. Aerts
Joachim G. J. V. Aerts
GPGiampiero Porzio
Giampiero Porzio

1 November 2020 in Clinical Lung Cancer
Verified
Journal Article
Closed access
ACAlessio Cortellini
Alessio Cortellini
AFAlex Friedlaender
Alex Friedlaender
Giuseppe BannaGiuseppe Banna
Giuseppe Banna
GPGiampiero Porzio
Giampiero Porzio
MBMelissa Bersanelli
Melissa Bersanelli
KCKatia Cannita
Katia Cannita

1 September 2017 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
Roberto IezziRoberto Iezzi
Roberto Iezzi
MPMaurizio Pompili
Maurizio Pompili
Alessandro PosaAlessandro Posa
Alessandro Posa
EAEleonora Annicchiarico
Eleonora Annicchiarico
MGMatteo Garcovich
Matteo Garcovich
CCCesare Colosimo
Cesare Colosimo

11 November 2019 in Mediators of Inflammation
Verified
Journal Article
Open access
CCCarmine Carbone
Carmine Carbone
GPGeny Piro
Geny Piro
VNVincenzo Di Noia
Vincenzo Di Noia
EDEttore D’argento
Ettore D’argento
EVEmanuele Vita
Emanuele Vita
EBEmilio Bria
Emilio Bria
Lung cancer is one of the deadliest and most common malignancies in the world, representing one of the greatest challenges in cancer treatment. Immunotherapy is rapidly changing standard treatment schedule and outcomes for patients with advanced malignancies. However, several ongoing studies are still attempting to elucidate the biomarkers that could predict treatment response as well as the new strategies to improve antitumor immune system response ameliorating immunotherapy efficacy. The complex of bacteria, fungi, and other microorganisms, termed microbiota, that live on the epithelial barriers of the host, are involved in the initiation, progression, and dissemination of cancer. The functional role of microbiota has attracted an accumulating attention recently. Indeed, it has been demonstrated that commensal microorganisms are required for the maturation, education, and function of the immune system regulating the efficacy of immunotherapy in the anticancer response. In this review, we discuss some of the major findings depicting bacteria as crucial gatekeeper for the immune response against tumor and their role as driver of immunotherapy efficacy in lung cancer with a special focus on the distinctive role of gut and lung microbiota in the efficacy of immunotherapy treatment.

12 March 2018 in Future Oncology
Verified
Journal Article
Closed access
SRSabrina Rossi
Sabrina Rossi
VNVincenzo Di Noia
Vincenzo Di Noia
LTLaura Tonetti
Laura Tonetti
ASAntonia Strippoli
Antonia Strippoli
MBMichele Basso
Michele Basso
EDEttore D'Argento
Ettore D'Argento
Aim: To evaluate gefitinib outcomes in EGFR-mutated non-small-cell lung cancer (NSCLC) patients harboring EGFR mutations, according to their sarcopenia status. Patients & methods: We retrospectively evaluated 33 patients with advanced NSCLC and EGFR mutations (exon 19 or 21), dividing them into sarcopenic patients, with low skeletal muscle index ≤39 cm2/m2 for women and ≤55 cm2/m2 for men, and nonsarcopenic patients. Results: Sarcopenia does not affect response to gefitinib treatment in EGFR mutated NSCLC patients, even if it is a bad prognostic indicator for overall survival (p = 0.035). Conclusion: Early recognition of sarcopenia is beneficial for prevention of cancer cachexia and detection of patients at potential risk of serious adverse events. Gefitinib dosage should be reduced and modulated in sarcopenic patients.